Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage, has been reported after 2 years of UDCA therapy. Thus, longer follow–up may be necessary to determine whether UDCA has a favorable effect on histological stage of disease and progression to cirrhosis. Our aim was to determine the long–term effects of UDCA therapy on histological stage and progression to cirrhosis in patients with PBC. Sixteen unselected patients with noncirrhotic PBC who had been on long–term UDCA therapy (13–15 mg/kg/d) for 6.6 ± 0.4 years (range, 5–9 years) were identified and their histological finding during treatment compared with that of 51 noncirrhotic patients with PBC who had received ineffective therapy (d–penicillamine [DPCA] or placebo) for 5.6 ± 0.07 years (range, 5–8 years). Histological stage was determined using the Ludwig classification. The rate of progression to cirrhosis (stage 4) was significantly less in the UDCA group than in the control group (13% vs. 49%P= .009). Although the overall rate of progression of histological stage was less in the UDCA group than in the control group (50% vs. 71%), this difference was not significant (P= .1). A marked improvement in liver biochemistries and Mayo risk score was noted in all patients during UDCA therapy; however, this improvement was not significantly different between patients who progressed and those who did not. In conclusion, long–term UDCA therapy appeared to delay the development of cirrhosis in PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationKaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
COMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Self-citation
Research works printed but not linked: 7
- Combes, 1995, Hepatology, 22, 759
- Emmond, 1996, Hepatology, 24, 168a
- Dickson, 1989, 10 Hepatology, 97, 1
- Kilmurry, 1996, Hepatology, 23, 1148
- Batts, 1996, Am J Gastroenterol, 91, 2314
- Lindor, 1995, Hepatology, 22, 1158
- Kaplan, 1987, Adv Inten Med, 32, 359
Cited by
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
“[128] AnguloP,BattsKP,TherneauTM,JorgensenRA,DicksonER,Lindor KD.”
Background(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“Several randomized trials, combined analyses, and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation.(53,56-67) Accordingly, UDCA is the initial drug of choice for PBC therapy.”
BackgroundResultSelf-citationParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Self-citationHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Self-citationCorpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationThe effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R.-E., & Poupon, R. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 390
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
Primary biliary cirrhosis: A 2010 update
Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.027 · Cited by 274
“In an early study [138], the rate of progression to cirrhosis after a follow-up period of 6 years was 13% in patients receiving UDCA and 49% in the control group of patients.”
BackgroundUrsodeoxycholic acid for primary biliary cirrhosis
Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub3 · Cited by 270
Liermann Garcia, R. F., Garcia, C. E., McMaster, P., & Neuberger, J. (2001) · Hepatology · doi:10.1053/jhep.2001.20894 · Cited by 254
“Bilirubin (mmol/L) 151 (23-623) 142 (6-1300) .”
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Nakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., Sano, K., Kondo, F., Fukusato, T., Tsuneyama, K., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2009.02500.x · Cited by 224
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 221
“Several randomized controlled clinical trials have shown that long-term administration of UDCA in PBC patients delays histological progression to cirrhosis and prolongs survival without liver transplantation (151-157).”
BackgroundSelf-citationOdin, J. A., Huebert, R. C., Casciola-Rosen, L., LaRusso, N. F., & Rosen, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200110716 · Cited by 220
Poupon, R. E., Lindor, K. D., Parés, A., Chazouillères, O., Poupon, R., & Heathcote, E. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00192-2 · Cited by 217
“However, two of these studies have some limitations: first, one is based on a very small number of patients [7]; second, in both studies the duration of UDCA therapy was highly variable [7,9].”
BackgroundResultInfluentialSelf-citationAl Mamari, S., Djordjevic, J., Halliday, J. S., & Chapman, R. W. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.013 · Cited by 204
Management Strategies for Liver Fibrosis
Altamirano-Barrera, A., Barranco-Fragoso, B., & Méndez-Sánchez, N. (2017) · Annals of Hepatology · doi:10.5604/16652681.1226814 · Cited by 191
Angulo, P., Jorgensen, R. A., Keach, J. C., Dickson, R. E., Smith, C., & Lindor, K. D. (2000) · Hepatology · doi:10.1002/hep.510310209 · Cited by 179
“Patients were excluded for the following reasons: (1) pregnancy; (2) anticipated need for liver transplantation within 1 year with less than 80% 1-year survival without liver transplantation as determined by the Mayo risk score22; (3) complications of cirrhosis such as recurrent variceal bleeds, spontaneous encephalop…”
BackgroundSelf-citationCharatcharoenwitthaya, P., Pimentel, S., Talwalkar, J. A., Enders, F. T., Lindor, K. D., Krom, R. A. F., & Wiesner, R. H. (2007) · Liver Transplantation · doi:10.1002/lt.21124 · Cited by 179
Self-citationCorpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169
Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30163-8 · Cited by 155
Neuman, M. G., Angulo, P., Malkiewicz, I. M., Jorgensen, R. A., Shear, N. H., Dickson, E. R., Haber, J. A., Katz, G. G., & Lindor, K. D. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02672.x · Cited by 147
Self-citationNakamura, M., Shimizu‐Yoshida, Y., Takii, Y., Komori, A., Yokoyama, T., Ueki, T., Daikoku, M., Yano, K., Matsumoto, T., Migita, K., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.016 · Cited by 136
“All PBC patients were histologically diagnosed based on internationally accepted criteria [17,18] and classified by Scheuer’s classification [19] using specimens obtained by needle liver biopsy.”
MethodResultYou, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
“Many randomized controlled trials and meta-analyses demonstrated that UDCA can improve biochemical variables [103–105], halt the disease progression [106, 107] and prolong the liver transplant-free survival [108, 109].”
BackgroundFat-soluble vitamin levels in patients with primary biliary cirrhosis
Phillips, J. R., Angulo, P., Petterson, T., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04134.x · Cited by 118
“UDCA at a dose of 13–15 mg/kg/day improves liver biochemistries (14), delays disease progression (18) and prolongs survival free of liver transplantation (19).”
BackgroundSelf-citationArenas, F., Hervías, I., Úriz, M., Joplin, R., Prìeto, J., & Medina, J. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33156 · Cited by 122
Bowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A., Forman, L. M., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.09.050 · Cited by 105
Ursodeoxycholic Acid and Long-Term Survival in Primary Biliary Cirrhosis
Levy, C., & Angulo, P. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04094.x · Cited by 99
Self-citationHeubi, J. E., Wiechmann, D. A., Creutzinger, V., Setchell, K. D. R., Squires, R. H., Couser, R. J., & Rhodes, P. G. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.125802 · Cited by 100
Harms, M. H., Lammers, W. J., Thorburn, D., Corpechot, C., Invernizzi, P., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., Floreani, A., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.440 · Cited by 109
Self-citationNatural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89
Angulo, P., Patel, T., Jorgensen, R. A., Therneau, T. M., & Lindor, K. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18663 · Cited by 88
“Patients were excluded for the following reasons: (1) pregnancy; (2) anticipated need for liver transplantation within 1 year with , 80% 1-year survival without liver transplantation as determined by the Mayo risk score23; (3) complications of cirrhosis such as recurrent variceal bleeds, spontaneous encephalopathy, di…”
BackgroundSelf-citationGuy, J. E., Qian, P., Lowell, J. A., & Peters, M. G. (2005) · Liver Transplantation · doi:10.1002/lt.20511 · Cited by 90
Use of ursodeoxycholic acid in liver diseases
Kumar, D., & Tandon, R. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02376.x · Cited by 99
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis
Furukawa, M., Moriya, K., Nakayama, J., Inoue, T., Momoda, R., Kawaratani, H., Namisaki, T., Sato, S., Douhara, A., Kaji, K., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13509 · Cited by 92
Ursodeoxycholic acid for primary biliary cirrhosis
Gluud, C. N., & Christensen, E. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551 · Cited by 98
Use of ursodeoxycholic acid in patients with liver disease
Angulo, P. (2002) · Current Gastroenterology Reports · doi:10.1007/s11894-002-0036-9 · Cited by 89
Self-citationAzemoto, N., Abe, M., Murata, Y., Hiasa, Y., Hamada, M., Matsuura, B., & Onji, M. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0051-9 · Cited by 92
Jun, I., Izumi, N., Nishimura, Y., Inoue, K., Ueda, K., Nakanishi, H., Tsuchiya, K., Hamano, K., Asahina, Y., Kurosaki, M., et al. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 85
Ursodeoxycholic acid for primary biliary cirrhosis
Gong, Y., Huang, Z. B., Christensen, E., & Gluud, C. N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub2 · Cited by 94
Primary biliary cholangitis: Old and novel therapy
Floreani, A., & Mangini, C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.06.020 · Cited by 82
Proposal of a new staging and grading system of the liver for primary biliary cirrhosis
Hiramatsu, K., Aoyama, H., Zen, Y., Aishima, S., Kitagawa, S., & Nakanuma, Y. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02537.x · Cited by 78
Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis
Silveira, M. G., Suzuki, A., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22458 · Cited by 68
Self-citationClinical Epidemiology of Primary Biliary Cirrhosis: Incidence, Prevalence, and Impact of Therapy
Lazaridis, K. N., & Talwalkar, J. A. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225653.07932.8f · Cited by 69
Evaluation of Fatigue in U.S. Patients with Primary Biliary Cirrhosis
Stanca, C. M., Bach, N., Krause, C., Tandon, N., Freni, M. A., Gutierrez, J. A., Bodian, C., Lopez, J., Berk, P. D., Bodenheimer, H. C., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41315.x · Cited by 63
Mason, A. L., Lindor, K., Bacon, B. R., Vincent, C., Neuberger, J., & Wasilenko, S. T. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03799.x · Cited by 58
Self-citationNakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Predicting outcome in primary biliary cirrhosis
Lammers, W. J., Kowdley, K. V., & van Buuren, H. R. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30838-5 · Cited by 59
“17,26 A combined analysis, which also used data from a Canadian and Spanish trial, showed that histologic progression was delayed after 2 years treat-ment, but that UDCA treatment was not associated with regression of fibrosis.”
Harms, M. H., Janssen, Q. P., Adam, R. A., Duvoux, C., Mirza, D. F., Hidalgo, E. L., Watson, C. J. E., Wigmore, S. J., Pinzani, M., Isoniemi, H., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15060 · Cited by 58
Azemoto, N., Kumagi, T., Abe, M., Konishi, I., Matsuura, B., Hiasa, Y., & Onji, M. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00782.x · Cited by 54
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 55
Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the pastissues for the future
Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80232-9 · Cited by 56
Varices in early histological stage primary biliary cirrhosis
Ali, A. H., Sinakos, E., Silveira, M. G., Jorgensen, R. A., Angulo, P., & Lindor, K. D. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181f18c4e · Cited by 50
Self-citationNevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 55
Obeticholic acid for the treatment of primary biliary cholangitis
Ali, A. H., & Lindor, K. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218471 · Cited by 47
Self-citationOld and new treatments for primary biliary cholangitis
Chascsa, D. M. H., Carey, E. J., & Lindor, K. D. (2017) · Liver International · doi:10.1111/liv.13294 · Cited by 56
Self-citationSecond opinion pathology in liver biopsy interpretation
Bejarano, P. A., Koehler, A., & Sherman, K. E. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05273.x · Cited by 49
“Because early use of ursodeoxycholic acid is believed to reduce fibrotic progression in PBC, this delay is likely to be detrimental (30).”
BackgroundMahrouf‐Yorgov, M., de l’Hortet, A. C., Cosson, C., Slama, A., Abdoun, E., Guidotti, J., Fromenty, B., Mitchell, C., & Gilgenkrantz, H. (2011) · Rejuvenation Research · doi:10.1089/rej.2010.1146 · Cited by 52
Efe, C., Taşçılar, K., Henriksson, I., Lytvyak, E., Alalkim, F., Trivedi, H. D., Eren, F., Eliasson, J., Beretta‐Piccoli, B. T., Fischer, J., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000290 · Cited by 52
Nguyen, D. L., Juran, B. D., & Lazaridis, K. N. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.07.006 · Cited by 44
PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 47
Self-citationNatural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era
Goel, A., & Kim, W. R. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.007 · Cited by 51
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis
Jorgensen, R. A., Angulo, P., Dickson, E. R., & Lindor, K. D. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.06043.x · Cited by 46
“Four of these 22 patients were part of the group who underwent repeat liver biopsy (7).”
BackgroundInfluentialSelf-citationThe value of antinuclear antibodies in primary biliary cirrhosis
Gao, L., Tian, X., Liu, B., & Zhang, F. (2008) · Clinical and Experimental Medicine · doi:10.1007/s10238-008-0150-6 · Cited by 47
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
Jhaveri, M. A., & Kowdley, K. V. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s113052 · Cited by 46
“It shows improvement in liver biochemistries, slows the histologic progression of the disease and also improves overall survival, at least in those treated in the early stages of the disease.(31,32) ter Borg et al(33) conducted a prospective cohort study of 297 PBC patients and showed that administration of UDCA in pa…”
A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.
Onofrio, F. Q., Hirschfield, G. M., & Gulamhusein, A. F. (2019) · Europe PMC (PubMed Central) · Cited by 58
Siegel, J. L., Jorgensen, R., Angulo, P., & Lindor, K. D. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200308000-00018 · Cited by 40
“UDCA is a well-tolerated drug, and patients rarely report side effects.(17) In a previously published study, we found that only 12% of patients reported side effects, which included hypertension, creatinine elevation, thrombocytopenia, leukopenia, nausea/vomiting, diarrhea, fever, and rash, but these occurred in the s…”
ResultSelf-citationAngulo, P., Jorgensen, R. A., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05270.x · Cited by 39
“lays disease progression (20, 21), and prolongs survival free”
BackgroundSelf-citationNew therapeutical indications of ursodeoxycholic acid.
Copaci, I., Micu, L., Iliescu, L. E., & Voiculescu, M. (2005) · PubMed · Cited by 45
Montaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Zhang, X.-X. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i12.3554 · Cited by 38
New Therapies for Primary Biliary Cirrhosis
Floreani, A., Franceschet, I., Perini, L., Cazzagon, N., Gershwin, M. E., & Bowlus, C. L. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8456-5 · Cited by 38
“All studies have demonstrated a significant improvement in serum markers of cholestasis and biliary injury together with a consistent reduction of IgM and AMA titers [14–21].”
BackgroundRisk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis
Ishibashi, H., Komori, A., Shimoda, S., Ambrosini, Y. M., Gershwin, M. E., & Nakamura, M. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4462 · Cited by 42
Taşçı, İ., Mas, M. R., Vural, S. A., Cömert, B., Alcigir, G., Serdar, M. A., Mas, N., Işık, A. T., & Ateş, Y. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01210.x · Cited by 33
“Long-term UDCA therapy significantly delays the development of cirrhosis in primary biliary cirrhosis (27, 28), which partly represents one of the most widely used liver fibrosis models on animals.”
BackgroundCurrent management of primary biliary cirrhosis and primary sclerosing cholangitis
Levy, C., & Lindor, K. D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00006-0 · Cited by 33
“These results were in agreement with a previous case-control study showing delayed onset of cirrhosis in UDCA-treated patients [39] and with a double-blind controlled multicentric study involving 192 patients with a mean time between biopsies of almost 5 years [40].”
ResultSelf-citationNatural history and management of primary biliary cirrhosis
Kumagi, T., & Al‐Harthy, N. (2012) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s25998 · Cited by 37
“26 Their study confirms the diagnostic performance and accuracy of transient elastography in the noninvasive quantification of liver fibrosis in PBC. Additional autoimmune diseases are commonly observed in patients with PBC.”
InfluentialOptions for Treatment of Primary Biliary Cirrhosis
Oo, Y. H., & Neuberger, J. (2004) · Drugs · doi:10.2165/00003495-200464200-00001 · Cited by 31
Primary biliary cirrhosis: proposal for a new simple histological scoring system
Wendum, D., Boëlle, P., Bédossa, P., Zafrani, E., Charlotte, F., Saint‐Paul, M., Michalak, S., Chazouillères, O., & Corpechot, C. (2014) · Liver International · doi:10.1111/liv.12620 · Cited by 28
“Ursodeoxycholic acid (UDCA) is the current therapy and can slow disease progression (2, 3).”
BackgroundUpdate on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.
Bahar, R., Wong, K. A., Liu, C. H., & Bowlus, C. L. (2018) · Europe PMC (PubMed Central) · Cited by 32
Hepatocellular Carcinoma in Primary Biliary Cholangitis
Sy, A. M., Ferreira, R., & John, B. V. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.011 · Cited by 33
Primary biliary cirrhosis and bile acids
Corpechot, C. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70016-5 · Cited by 28
Carbone, M., Harms, M. H., Lammers, W. J., Marmon, T., Pencek, R., MacConell, L., Shapiro, D., Jones, D. E., Mells, G. F., & Hansen, B. E. (2018) · Hepatology Communications · doi:10.1002/hep4.1180 · Cited by 31
“In many cases, the disease is detected at an early stage and treatment with ursodeoxycholic acid (UDCA) improves biochemistry, impedes hepatic fibrosis, and can restore normal life expectancy.((3-5)) However, in a substantial proportion of patients, the response to treatment with UDCA is inadequate.”
BackgroundTreatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
Self-citationRisk factors for hepatic decompensation in patients with primary biliary cirrhosis
Shi, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i7.1111 · Cited by 30
Färkkilä, M., Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., & Niemelä, O. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01722.x · Cited by 26
Current Status of Liver Transplantation for Primary Biliary Cholangitis
Aguilar, M. T., & Carey, E. J. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.011 · Cited by 26
Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Rust, C., & Beuers, U. H. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:135 · Cited by 28
Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fi brosis
Mas, N., Taşçı, İ., Cömert, B., Öçal, R., & Mas, M. R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1108 · Cited by 25
Kubota, J., Ikeda, F., Terada, R., Kobashi, H., Fujioka, S.-I., Okamoto, R., Baba, S., Morimoto, Y., Ando, M., Makino, Y., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0090-2 · Cited by 23
“Ursodeoxycholic acid (UDCA) delays histological progression (24-29), and prolongs survival without liver transplantation (30, 31).”
BackgroundNatural history of primary biliary cirrhosis
Abe, M., & Onji, M. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00351.x · Cited by 26
Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression
Paumgartner, G. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00243-5 · Cited by 27
“Three studies [8–10] reported an effect of UDCA on the histologic progression of PBC, but two of them are limited by a small number of patients [8] or variable duration of therapy [8,10].”
BackgroundResultBuko, V., Lukivskaya, O., Naruta, E. E., Belonovskaya, E., & Tauschel, H. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.02.001 · Cited by 23
Jaundice Caused by the Vanishing Bile Duct Syndrome in a Child With Hodgkin Lymphoma
Yusuf, M. A., Elias, E., & Hübscher, S. G. (2000) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200003000-00014 · Cited by 23
Cetirizine-induced Cholestasis
Fong, D. G., Angulo, P., Burgart, L. J., & Lindor, K. D. (2000) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200010000-00016 · Cited by 23
Self-citationThe immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Metadata
- Authors
- Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 1999-03
- Volume
- 29
- Issue
- 3
- Pages
- 644-647
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1993958712
- Cited by
- 234
- References
- 24
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 10 · 2021: 2 · 2020: 5 · 2019: 11 · 2018: 15 · 2017: 12 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6028 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, histological progression, long-term treatment, Ludwig classification, D-penicillamine, Mayo risk score, cholestatic liver disease, liver histopathology
- MeSH terms
- Adult, Aged, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Middle Aged, Penicillamine, Time Factors, Ursodeoxycholic Acid, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.